Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
275 stopped studies mapped to Malignant Urinary Tract Neoplasm and descendants · 93% state a reason
Over the 275 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01284205 | First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC | Phase 3 | withdrawn | Jan 26, 2011 | Bioniche Life Sciences Inc. | This indication is not being pursued at this point in time. | Other (stated, no rule matched) |
| NCT01688414 | Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer | N/A | withdrawn | Sep 19, 2012 | Stanford University | PI left Stanford | Investigator |
| NCT00112905 | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01907308 | Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma | Phase 2 | withdrawn | Jul 24, 2013 | University of Colorado, Denver | Sponsor's decision to terminate the study | Sponsor / business decision |
| NCT00802633 | Radical Cystectomy: Can We Improve Our Surgical Technique With the Ligasure Impact… | N/A | terminated | Dec 5, 2008 | Vanderbilt University | Enrollment was stopped after eighty patients were enrolled. | Enrollment / accrual |
| NCT01639521 | Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine,… | Phase 2 | withdrawn | Jul 12, 2012 | University of Southern California | Lack of funding | Funding |
| NCT00014287 | Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer | Phase 1 | withdrawn | Jan 7, 2004 | University of Pittsburgh | not stated | Not stated |
| NCT01496534 | Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients… | Phase 1 | terminated | Dec 21, 2011 | Matthew Galsky | toxicity of combination of medications | Safety / toxicity |
| NCT01010334 | Comparison of Standard of Care or Treatment on Protocol | N/A | terminated | Nov 10, 2009 | New Mexico Cancer Research Alliance | PI deparature and very low (\<2%) accrual rate.(No results required) | Enrollment / accrual |
| NCT00084578 | Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic… | N/A | withdrawn | Jun 11, 2004 | Fox Chase Cancer Center | Withdrawn due to drug toxicity | Safety / toxicity |
| NCT00516750 | Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving… | Phase 2 | terminated | Aug 15, 2007 | Kyoto University | Withdrawn due to lack of enrollment. | Enrollment / accrual |
| NCT01282333 | Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced… | Phase 1 | terminated | Jan 25, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00004856 | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic… | Phase 2 | terminated | Sep 30, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01700010 | Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer | Phase 2 | withdrawn | Oct 4, 2012 | University of Michigan Rogel Cancer Center | Funding issues. | Funding |
| NCT01245660 | A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy(LAPAINBLAD) | Early Phase 1 | terminated | Nov 22, 2010 | University Hospital, Bordeaux | The rythm of enrollment was not compatible with the objective of recruitement in the research. | Enrollment / accrual |
| NCT00087295 | S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium | Phase 2 | terminated | Jul 12, 2004 | SWOG Cancer Research Network | Permanently Closed Due to Poor Accrual | Enrollment / accrual |
| NCT01551407 | Detection of Bladder Tumors After 30 Min Instillation of Hexvix | Phase 2 | terminated | Mar 12, 2012 | Photocure | slow inclusion rate | Other (stated, no rule matched) |
| NCT00042887 | Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer | Phase 3 | terminated | Jan 27, 2003 | European Organisation for Research and Treatment of Cancer - EORTC | low accrual | Enrollment / accrual |
| NCT00147238 | A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic… | N/A | terminated | Sep 7, 2005 | M.D. Anderson Cancer Center | Terminated at request of sponsor. | Other (stated, no rule matched) |
| NCT00237575 | Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin &… | Phase 3 | terminated | Oct 12, 2005 | University of Kentucky | not stated | Not stated |
| NCT00003824 | S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer | Phase 3 | terminated | Apr 14, 2004 | SWOG Cancer Research Network | Permanently Closed Due to Poor Accrual | Enrollment / accrual |
| NCT00003640 | Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II… | Phase 2 | terminated | May 20, 2004 | European Organisation for Research and Treatment of Cancer - EORTC | low accrual | Enrollment / accrual |
| NCT00003642 | Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II… | Phase 2 | terminated | Apr 9, 2004 | European Organisation for Research and Treatment of Cancer - EORTC | low accrual | Enrollment / accrual |
| NCT01215266 | Sorafenib in Urothelium Cancer of Bladder | Phase 2 | terminated | Oct 6, 2010 | Association of Urologic Oncology (AUO) | Slow recruitment | Enrollment / accrual |
| NCT00216814 | Antiangiogenic Effects of BCG on Urinary Concentration of Angiogenic Factors | — | terminated | Sep 22, 2005 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | No funding and data was not appropriate to consider continuing. | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 29, 2014source: clinicaltrials